Jim Krenn

Jim Krenn

Education

University of Notre Dame (B.B.A., 2005)
Harvard Law School (J.D., 2008)

Bar Admissions

California

Jim Krenn has extensive experience representing public and private companies and investors in corporate and securities matters. Mr. Krenn structures, negotiates and advises clients on financing and acquisition transactions and general corporate matters.

Mr. Krenn has represented clients in over $1 billion in equity and debt financings ranging from seed rounds to $100 million plus later stage rounds. He has also represented buyers and sellers in acquisitions and divestitures ranging from $1 million to over $1 billion, including stock purchases, asset purchases, mergers, tender offers, acquisitions and divestitures of divisions and subsidiaries, cross-border transactions and auction transactions.

Mr. Krenn counsels private and public companies on a broad range of significant business transactions from formation through liquidity, including private financings, mergers and acquisitions, public securities offerings and SEC compliance and reporting. Mr. Krenn also advises angel, corporate and venture capital investors in connection with investments, as well as liquidity and exit strategies. In addition, Mr. Krenn advises boards of directors on governance and compliance matters.

Mr. Krenn has represented clients in a broad range of industries, including biopharmaceutical, artificial intelligence, medical device, e‑commerce, cybersecurity, software, internet, social media, semiconductor, unmanned aerial vehicles, agtech, consumer products, finance, cleantech, energy and action sports.

Mr. Krenn was recognized as “Best of the Bar” by the San Diego Business Journal in 2015. Mr. Krenn received his J.D., cum laude, from Harvard Law School. Mr. Krenn received his B.B.A., summa cum laude, in finance from the University of Notre Dame, where he was a recipient of the Hamilton Finance Award and the Eugene D. Fanning Award for exceptional achievement in business communication.

Representative Matters:

MERGERS AND ACQUISITIONS

  • California Cryobank, a private equity-backed leader in reproductive tissue donor services and stem cell banking, in multiple acquisitions.
  • Clean Energy Fuels (NASDAQ: CLNE), a provider of natural gas as an alternative fuel for vehicle fleets, in its sale for up to $180 million of components of its renewable natural gas business to BP (NYSE: BP). 
  • John Deere (NYSE: DE), in its announced acquisition of the precision planning unit of Monsanto (NYSE: MON) for an undisclosed sum.
  • Mitchell International, a developer of smart technology solutions that simplify and accelerate claims handling, repair processes, and pharmacy transactions, in its acquisition of Cogent Works for an undisclosed sum.
  • Biotix, a private equity-backed developer and manufacturer of laboratory consumables and liquid handling solutions, in its sale to Mettler-Toledo (NYSE: MTD) for an undisclosed sum.
  • Adicet Bio, a biopharmaceutical company focused on the development of next-generation cell immunotherapies, in its cross-border acquisition of Applied Immune Technologies for an undisclosed sum.
  • Astute Medical, a medical diagnostic company focusing on high-risk medical conditions and diseases, in its $90 million sale to bioMérieux (EPA: BIM).
  • Mentor, a leading supplier of medical products for the global aesthetic market, in its $1.12 billion sale to Johnson & Johnson (NYSE: JNJ).
  • Wavestream, a provider of high power solid state amplifiers, in its $137 million sale to Spacenet, a subsidiary of Gilat Satellite Networks (NASDAQ: GILT).
  • Cogent, a biometric identification solutions provider, in its $943 million sale to 3M (NYSE: MMM).
  • Alaska Energy & Resources Company, the parent company of a regulated electric utility in Alaska, in its $170 million sale to Avista (NYSE: AVA).

VENTURE FINANCINGS

  • Petuum, an artificial intelligence and machine learning software infrastructure provider, in its $93 million Series B financing.
  • Rakuten Aspyrian, a biotechnology company developing a new class of precision targeted oncologic drugs, in over $230 million of equity financings.
  • Adicet Bio, a biopharmaceutical company focused on the development of next-generation cell immunotherapies, in its Series A financing of up to $51 million.
  • Forward Ventures as an investor in multiple equity financings, convertible debt financings and M&A transactions, including transactions involving HemaQuest Pharmaceuticals, LigoCyte Pharmaceuticals, Ambit Biosciences and Syndax Pharmaceuticals.
  • Solarflare Communications, a provider of application-intelligent networking I/O software and hardware platforms, in over $200 million of equity and debt financings.
  • Astute Medical, a medical diagnostic company focusing on high-risk medical conditions and diseases, in over $200 million of equity and debt financings.
  • Oak Investment Partners, as an investor in multiple equity financings, including MobiTV and Brit Media.
  • VoloAgri, an agriculture technology company focused on seed genetics, in its $56 million Series B Preferred Stock financing and $69 million Series C Preferred Stock financing.
  • Greenoaks Capital Partners and its affiliates as investors in over $100 million in equity financings, debt financings and secondary transactions, including Coupang and several other prominent e-commerce companies.
  • ACEA Biosciences, a developer of cell analysis instrumentation technologies, in its $30 million Series E Preferred Stock financing.
  • California Cryobank, a private equity-backed leader in reproductive tissue donor services and stem cell banking, in multiple equity and debt financings.
  • Western Digital Capital as an investor in multiple equity financings, including investments in Hightail and Upthere.

CAPITAL MARKETS

  • B. Riley Financial (NASDAQ: RILY), a diversified financial services company, in its $53 million private placement and merger with investment banking firm B. Riley & Co.
  • Inovio Pharmaceuticals (NASDAQ: INO), a developer of active DNA immunotherapies and vaccines and delivery devices to prevent and treat cancers and infectious diseases, in its $30 million registered direct offering.
  • Netlist (NASDAQ: NLST), a producer of next generation persistent memory solutions, in its $10 million registered direct offering.
  • OncoSec (NASDAQ: ONCS), a developer of DNA-based intratumoral cancer immunotherapies, in its $10 million registered direct offering. 

MoFo ScaleUp

Email Disclaimer

Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

©1996-2018 Morrison & Foerster LLP. All rights reserved.